TMO · Thermo Fisher Scientific

The thesis

Thermo Fisher Scientific's case rests on biopharma services growth that produced a third-quarter beat and a raised 2026 outlook, backed by a $5 billion buyback authorized on 5 November 2026. The rating is Medium because those results support modest outperformance, while a 4% fourth-quarter organic growth guide caps the room for upside. The fourth-quarter report and first 2027 guidance, expected around 28 January 2027, settle whether growth holds.

On 21 October 2026 the company reported third-quarter revenue of $12.14 billion, up 9%, with 6% organic growth. Organic growth excludes acquisitions, divestitures and currency. Adjusted earnings per share (EPS) were $6.68, up 15%. Management raised 2026 guidance to revenue of $47.7–$48.2 billion and adjusted EPS of $25.13–$25.43, and kept fourth-quarter organic growth guidance at 4%. The 10-Q filed on 30 October 2026 confirms quarterly revenue of $12.14 billion against $11.12 billion a year earlier.

The shares closed at $699.44 on 12 November 2026, down from $717.71 the session before. Company news carried no company-specific announcement for that session. The price already reflects the post-earnings rerating: the shares are up 19.0% over three months and sit 3.9% below the quoted 52-week high of $727.56 set on 11 November 2026.

Bullish and bearish views on Thermo Fisher Scientific, Inc.

The bull case on Thermo Fisher Scientific, Inc. (TMO), in brief: buyback capacity is back to $5 billion. The bear case: fourth-quarter outlook stays at 4%.

Bull case

• Buyback capacity is back to $5 billion. The board authorized up to $5 billion of repurchases on 5 November 2026, with no expiration date, replacing an authorization with $1 billion remaining. The company repurchased $4.0 billion of stock in the first nine months of 2026, according to its 21 October 2026 8-K.
• Biopharma services is the growth engine. Laboratory Products and Biopharma Services revenue was $6,863 million in the third quarter of 2026, the largest of four segments, according to the 8-K. Chief Financial Officer Jim Meyer said on the 21 October 2026 call that second-half organic growth guidance rose to 5% from 4%.
• Margins and cash flow improved together. Adjusted operating margin reached 24.5% in the third quarter, up from 23.3% a year earlier. Year-to-date free cash flow was $4,618 million against $3,319 million a year earlier, and full-year guidance rose to $7.0–$7.5 billion on 21 October 2026.
• Clario adds earnings and a data business. The $8.875 billion cash purchase of Clario, which supplies endpoint data for clinical trials, closed on 24 March 2026. The company expects it to add $0.45 of adjusted EPS in the first year after closing.
• The latest broker target sits above the shares. Argus Research kept its Buy rating and raised its target to $780 on 30 October 2026, according to Benzinga, above the 12 November 2026 close of $699.44.

Bear case

• Fourth-quarter outlook stays at 4%. Management kept fourth-quarter organic growth guidance at 4% on 21 October 2026, below the third quarter's 6%. The CFO said much of the pharma services strength fell in the third quarter because of the timing of customer activity.
• Part of the earnings beat was one-off. On the 21 October 2026 call, management attributed $0.15 of EPS outperformance against prior guidance to tariff refunds, against $0.08 from operations and $0.03 from currency.
• The bar for 2027 is modest. At the J.P. Morgan Healthcare Conference on 13 January 2026, Chief Executive Marc Casper framed organic growth of 3% to 6% for 2026 and 2027, with 7% or more from 2028, according to Pharmaceutical Technology's coverage. A 2027 guide near the low end would sit poorly with shares near a 52-week high.
• Buybacks lean partly on new debt. The company announced an 800 million Swiss franc bond issue in four tranches of 3 to 12 years on 2 November 2026, after paying $8.875 billion in cash for Clario in March.
• Insiders sold into strength. Chief Human Resources Officer Lisa Britt sold 2,831 shares in the open market at $706.45 on 28 October 2026, her Form 4 shows. President and Chief Operating Officer Gianluca Pettiti sold 4,133 shares at $614.38 on 31 August 2026 under a Rule 10b5-1 trading plan. Executive Vice President Michael Shafer will retire at the end of 2026, the company said on 30 October 2026.

Price setup

The 12 November 2026 close of $699.44 is below the highest close of the past year, $721.63 on 9 November 2026, and the quoted intraday 52-week high of $727.56 on 11 November 2026. The 52-week closing low was $438.34 on 15 May 2026, so the shares have recovered most of a year-long range in six months.

As of 12 November 2026, the 50-day moving average stood at $668.92 and the 200-day moving average at $554.21, both below the last close. The 50-day average is the nearest reference below the price. A move back through it would show the post-earnings rerating giving way. The three-month gain of 19.0% runs from a $588.29 close on 14 August 2026, before the 21 October 2026 report.

The 12 November 2026 decline gave back the gains of the two prior sessions. No dated company event accompanies it, so it reads as a pause near the high rather than a change in the business case.

Catalysts ahead

• ~12 January 2027 (est.): J.P. Morgan Healthcare Conference presentation. Management often gives early comments on the coming year here, ahead of formal 2027 guidance.
• ~28 January 2027 (est.): Fourth-quarter 2026 report and first 2027 guidance. Shows whether the 4% fourth-quarter organic outlook was conservative and where 2027 growth guidance lands within the 3%-6% framework set in January 2026.

What would change the view

A daily close below $650, under the 50-day moving average, which would give back much of the rally that followed the 21 October 2026 report. Fourth-quarter organic growth below the 4% guidance, or initial 2027 organic growth guidance below the 2026 rate, would also break the case.

The risks this note tracks, each with what would confirm it:

• Third-quarter pharma services strength reflected customer timing that does not repeat. Confirmed by: fourth-quarter organic growth at or below the 4% guidance, with management citing lower biopharma services activity.
• 2027 guidance resets growth lower after a strong 2026. Confirmed by: initial 2027 organic growth guidance below the 2026 rate, or near the low end of the 3%-6% framework, at the late-January report.
• Earnings quality is weaker than the headline beat suggests. Confirmed by: further EPS outperformance driven mainly by one-off items such as tariff refunds rather than operations.
• The share price runs ahead of broker targets as post-earnings raises fade. Confirmed by: new sell-side targets set below the 12 November 2026 close of $699.44, or target cuts outnumbering raises before the January report.
• Debt-funded buybacks raise leverage after the Clario purchase. Confirmed by: further bond issuance or a credit-rating outlook change tied to share repurchases.
• Insider selling broadens as the shares sit near their high. Confirmed by: further open-market sales on SEC Form 4 by senior officers outside Rule 10b5-1 plans.

What it trades with

Thermo Fisher's growth is tied to biopharma research and manufacturing spending, through its biopharma services segment and Clario's clinical-trial data business. Shifts in drug-company research budgets or biotech funding would likely move it alongside other life-science tools suppliers. The shares also track the broad market: the 9 November 2026 gain came on a day the S&P 500 rose 2.35% in a rally led by semiconductors, Yahoo Finance reported. Installations of the Optis electron microscope at unnamed chipmakers, announced on 10 November 2026, give the company a minor link to chip-equipment spending, small next to its biopharma exposure.